RT Journal Article
SR Electronic
T1 Humoral Immunogenicity of Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.22.21268217
DO 10.1101/2021.12.22.21268217
A1 Schell, Trevor L.
A1 Knutson, Keith L.
A1 Saha, Sumona
A1 Wald, Arnold
A1 Phan, Hiep S
A1 Almasry, Mazen
A1 Chun, Kelly
A1 Grimes, Ian
A1 Lutz, Megan
A1 Hayney, Mary S.
A1 Farraye, Francis A.
A1 Caldera, Freddy
YR 2021
UL http://medrxiv.org/content/early/2021/12/27/2021.12.22.21268217.abstract
AB Herein, we evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with IBD. All patients were seropositive and had higher antibody concentrations after the third dose than after completion of the two-dose primary series.Competing Interest StatementDr. Freddy Caldera has received research support from Takeda Pharmaceuticals. He has been a consultant for Takeda, Arena Pharmaceuticals, GSK, and Celgene. Dr. Farraye is a consultant for Arena, BMS, Braintree Labs, GSK, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer and Sebela. He sits on a DSMB for Lilly and Theravance. Dr. Hayney is a consultant for GSK Vaccines and Seqirus and has received research support from Takeda Pharmaceuticals, Dynavax, and Sanofi. Dr. Chun is an employee of LabCorp.Funding StatementThis study was funded by Takeda Pharmaceuticals and American College of Gastroenterology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board of University of Wisconsin School of Medicine and Public Health gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.